Last reviewed · How we verify
Aripiprazole 6-week group
Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychiatric disorders.
Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychiatric disorders. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Aripiprazole 6-week group |
|---|---|
| Also known as | Abilify® |
| Sponsor | Seoul National University Hospital |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2/D3 receptor (partial agonist); serotonin 5-HT1A receptor (partial agonist); serotonin 5-HT2A receptor (antagonist) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, providing dopaminergic stabilization rather than pure antagonism. This mechanism reduces excessive dopaminergic activity in hyperactive pathways while supporting activity in hypoactive pathways. It also has serotonin 5-HT1A partial agonist and 5-HT2A antagonist properties, contributing to its antipsychotic and mood-stabilizing effects.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute manic or mixed episodes)
- Major depressive disorder (adjunctive treatment)
- Irritability associated with autism spectrum disorder
Common side effects
- Akathisia
- Headache
- Anxiety
- Insomnia
- Nausea
- Weight gain
- Tremor
- Sedation
Key clinical trials
- Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia (PHASE4)
- Psychoeducational Group for Depression (NA)
- Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (PHASE4)
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL (NA)
- To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole 6-week group CI brief — competitive landscape report
- Aripiprazole 6-week group updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI